Drug Trial Radar · NCT01332019
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
Last checked: Nov 20, 2026Latest source record: Jan 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,077
Actual
Start
Apr 2011
Primary completion
Oct 2015
Study completion Oct 2015
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Apr 8, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the long-term safety and tolerability of peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this study is to describe long-term multiple sclerosis (MS) outcomes in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.
Conditions
- Relapsing Multiple Sclerosis
Interventions
peginterferon beta-1aDrug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Adverse Events (AEs) Serious AEs, and Discontinuations Due to AEsTime frame: up to 4 years
- Number of Participants With Potentially Clinically Significant Hematology Laboratory AbnormalitiesTime frame: up to 4 years
- Number of Participants With Shifts From Baseline: Liver Function Laboratory ValuesTime frame: Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years
- Number of Participants With Shifts From Baseline: Kidney Function and Other Blood ChemistryTime frame: Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years
- Number of Participants With Shifts From Baseline: UrinalysisTime frame: Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years
Locations
151 sites in 26 countries. Site status is shown where the registry gives one.
Research Site
Atlanta, Georgia
Research Site
Lexington, Kentucky
Research Site
Baltimore, Maryland
Research Site
Raleigh, North Carolina
Research Site
Akron, Ohio
Research Site
Cleveland, Ohio
Research Site
Franklin, Tennessee
Research Site
Sint-Truiden, Belgium
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
London, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Santiago, Chile
Research Site
Barranquilla, Colombia
Research Site
Bogotá, Colombia
Research Site
Zagreb, Croatia
Research Site
Brno, Czechia
Research Site
Havffov, Czechia
Research Site
Olomouc, Czechia
Research Site
Ostrava, Czechia
Research Site
Ostrava-Vitkovice, Czechia
Research Site
Prague, Czechia
Research Site
Prague, Czechia
Research Site
Teplice, Czechia
Research Site
Pärnu, Estonia
Research Site
Tallinn, Estonia
Research Site
Tartu, Estonia
Research Site
Amiens, France
Research Site
Bouches-du-Rhone, France
Research Site
Clermont-Ferrand, France
Research Site
Nice, France
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Bayreuth, Germany
Showing 40 of 151 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.